November 7, 2017 / 12:24 PM / a year ago

BUZZ-Valeant: Jumps as Q3 profit beats despite revenue drop

** Valeant Pharma’s US-listed shares up 12.7 pct at $13.57 premarket after Q3 results

** Beats Q3 profit estimates; earns $1.04/shr, above Wall St est of 88 cents, per TR I/B/E/S

** VRX revenue down 10 pct, hurt by declining sales in branded drugs division; posts adj profit of $367 mln vs $510 mln a year earlier

** Cuts revenue forecast for 2017, but keeps adjusted EBITDA forecast intact at $3.60-$3.75 bln

** VRX now expects FY revenue of $8.65-$8.80 bln vs prior view of $8.70-$8.90 bln

** Shares down 17 pct YTD (Reporting by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below